Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep ...

Welcome to Emergent BioSolutions Inc. fourth quarter 2024 earnings conference call. At this time, all participants are in a ...

Despite a dip in Q4 revenue, Emergent BioSolutions Inc (EBS) showcases significant profitability improvements and strategic ...

Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They ...

Emergent BioSolutions (EBS) is down -24.6%, or -$1.68 to $5.15.Discover the Best Stocks and Maximize Your Portfolio: See what stocks are ...

Emergent BioSolutions Inc.'s $40 million class action settlement of claims that it misled investors about its ability to ...

A drugmaker developing a brain tumor treatment is being acquired in a $935 million deal.

Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billionFourth Quarter 2024 Net Loss of $31.3 ...

Q4 2024 Earnings Call Transcript March 3, 2025 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is $0.05, ...

Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. fourth quarter 2024earnings conference call At this time, all participants are in a listen-only mode. After the ...

Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the ...